Business
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from multiple studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2022, taking place November 3-6 in Orlando, Florida. These presentations by several leading experts in nephrology build on the robust evidence supporting the long-term safety and efficacy profile of LUPKYNIS for the treatment of adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).\n\nThe abstracts for ASN Kidney Week 2022 are listed below and available online at: https://www.asn-online.org/education/kidneyweek/2022/program-search-abstract.aspx\n\nASN Kidney Week 2022 Oral and Poster Presentations:\n\nTitle: Efficacy and Safety of Voclosporin Over Three Years in Patients with Severe Lupus Nephritis\nPresenting author: Hanni Menn-Jospehy, M.D., Boston University School of Medicine, Boston, Massachusetts\nDate: Friday, November 4, 2022\nTime: 5:33 p.m - 5:42 p.m ET\nSession: FR-OR58\n\nTitle: Enlight-LN: A Prospective Observational Registry of Patients Treated with Voclosporin for Lupus Nephritis in the United States\nPresenting author: Keith J. Tagoe, Pharm.D., R.Ph., Aurinia Pharmaceuticals Inc, Rockville, Maryland\nDate: Thursday, November 3; Friday, November 4; Saturday, November 5, 2022\nTime: 10:00 a.m - 12:00 p.m ET\nSession: INFO36\n\nTitle: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study\nPresenting author: Dawn Caster, M.D., University of Louisville, Louisville, Kentucky\nDate: Friday, November 4, 2022\nTime: 10:00 a.m - 12:00 p.m ET\nSession: FR-PO640\n\nTitle: Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome Over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies\nPresenting author: Samir V. Parikh, M.D., The Ohio State University Wexner Medical Center, Columbus, Ohio\nDate: Thursday, November 3, 2022\nTime: 10:00 a.m - 12:00 p.m ET\nSession: TH-PO486\n\nTitle: Long-Term Safety and Efficacy Of Voclosporin in Patients With Lupus Nephritis and Low eGFR\nPresent...